2.48
전일 마감가:
$2.64
열려 있는:
$2.57
하루 거래량:
220.30K
Relative Volume:
0.70
시가총액:
$133.61M
수익:
$44.12M
순이익/손실:
$-156.25M
주가수익비율:
-0.8078
EPS:
-3.07
순현금흐름:
$-154.61M
1주 성능:
-5.70%
1개월 성능:
-4.25%
6개월 성능:
-44.02%
1년 성능:
-56.03%
2 Seventy Bio Inc Stock (TSVT) Company Profile
명칭
2 Seventy Bio Inc
전화
339-499-9300
주소
60 BINNEY STREET, CAMBRIDGE
TSVT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TSVT
2 Seventy Bio Inc
|
2.48 | 133.61M | 44.12M | -156.25M | -154.61M | -3.07 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-06 | 다운그레이드 | Goldman | Neutral → Sell |
2024-01-31 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-01-31 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
2023-10-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2023-10-12 | 개시 | Citigroup | Buy |
2023-09-13 | 다운그레이드 | Goldman | Buy → Neutral |
2023-09-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
2023-07-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-10-31 | 개시 | Guggenheim | Buy |
2022-05-02 | 개시 | Goldman | Buy |
2022-02-10 | 개시 | SVB Leerink | Outperform |
2022-01-06 | 개시 | Cowen | Outperform |
2021-11-09 | 개시 | Canaccord Genuity | Buy |
2021-11-08 | 개시 | Morgan Stanley | Overweight |
2021-11-08 | 개시 | Wedbush | Outperform |
모두보기
2 Seventy Bio Inc 주식(TSVT)의 최신 뉴스
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - Business Wire
2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World
2 Seventy Bio Inc (TSVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2 Seventy Bio Inc 주식 (TSVT) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
Eatwell Victoria | Chief Financial Officer |
Jan 06 '25 |
Sale |
2.78 |
97 |
270 |
338,979 |
Baird William D III | President and CEO |
Jan 03 '25 |
Sale |
2.94 |
31,718 |
93,121 |
862,889 |
Baird William D III | President and CEO |
Jan 06 '25 |
Sale |
2.78 |
763 |
2,120 |
862,126 |
Snow Jessica | See Remarks |
Dec 13 '24 |
Sale |
3.23 |
2,287 |
7,393 |
153,479 |
자본화:
|
볼륨(24시간):